CORT · Corcept Therapeutics Incorporated

Current Thesis

The post-CRL redemption arc that defined this name is now substantially complete. Stock round-tripped from the $28.66 CRL low (set after the 2025-12-31 hypercortisolism rejection) all the way to a $91.00 52-week high, clearing the pre-CRL $70 level, and has since faded to $72.62 (2026-06-05). The live leg is no longer "broken chart reclaims" it is the Cushing's second-approval optionality. On 2026-05-27 management announced it will resubmit the relacorilant NDA for Cushing's syndrome with no new trials required, FDA discussions described as constructive, PDUFA expected ~6 months post-filing (late 2026). Layered on top: a confirmed first-in-class oncology launch (Lifyorli) and FY2026 guidance raised to $950M–$1.05B. The catch Q1 2026 missed, the legacy base is decelerating, and a fresh entry at $72.62 is buying after a ~2.5x off the lows with the next hard binary still six months out. MATURING, not accelerating.

Bull Case

• Cushing's NDA resubmission announced 2026-05-27 the single biggest re-rating lever from the prior thesis is now in motion. No new clinical studies required; the CRL was for "additional evidence of effectiveness," and management says the supplementary analyses came back favorable. PDUFA expected ~6 months after filing → late-2026 action date. A second approval re-opens the larger endocrine TAM that the December CRL had capped.
• ASCO 2026 ROSELLA overall survival (presented 2026-05-29/30): Lifyorli + nab-paclitaxel cut risk of death 35% vs nab-paclitaxel alone HR 0.65, p=0.0004, median OS 16.0 months vs 11.9 months. Benefit held across all subgroups including recent taxane exposure, no biomarker testing required. Stock popped +15.4% on the print.
• Lifyorli launch traction: early uptake by 200+ physicians, NCCN guideline inclusion as preferred regimen, and a company framing that Lifyorli could exceed $1B in U.S. revenue by end of decade. List price $37,900 / 28-day cycle specialty-oncology economics on a former endocrine-only book.
• FY2026 guidance raised to $950M–$1.05B (up from the prior $900M–$1.0B), implying a back-half ramp as the oncology launch compounds on the Korlym base.
• Analyst PTs re-rated up post-resubmission: Canaccord Genuity Buy, PT to $135 (2026-05-28); HC Wainwright Buy, PT to $95 (2026-05-28). Consensus cluster $93–$135, Strong Buy. Spread runs ~28%–85% above spot.
• Balance sheet funds the dual launch: cash and investments of $515.4M at 2026-03-31; no financing overhang to dilute the move.

Bear Case

• Q1 2026 was a miss. Revenue $164.9M vs $157.2M (+4.9% YoY) a sharp deceleration from the double-digit growth that anchored the prior bull case and a net LOSS of $31.8M vs +$20.5M net income a year earlier, on launch spend and litigation. Reported 2026-04-30.
• Valuation has front-run the catalyst. P/E ~180 and a $7.80B market cap already discount a Cushing's approval that has not happened; the easy redemption money was made between $28.66 and $91.
• Sell-the-news tape. After the +15.4% ASCO pop to the $91 high, the stock gave back ~20% to $72.62 within a week distribution into good news, not accumulation.
• Litigation overhang. Amended complaint by a former employee disclosed 2026-06-03; securities class action (relacorilant disclosures) still live. Headline risk into every bounce.
• Catalyst gap. The Cushing's PDUFA sits ~6 months out a dead-money / binary window where the stock can drift or de-rate before the next hard event, and an FDA refuse-to-file or second CRL would be a violent reset.
• Legacy base risk. Generic mifepristone / patent overhang on Korlym, the revenue stream funding the pipeline, plus payor pushback risk on $37,900/cycle pricing in a small platinum-resistant ovarian funnel.

Setup & Price Structure

• $72.62 (2026-06-05 close), 52-week range $28.66 $91.00, market cap $7.80B, P/E ~180.
• Fully reclaimed the CRL crash and printed new highs at $91, then a ~20% give-back the chart is no longer "broken," it is extended-and-cooling.
• Theme membership narrowed to a single tag and flipped to MATURING (theme discovery 2026-06-05); the "post-CRL recovery" and "first-in-class oncology launch" tags rolled off as the move matured.
• Structure now hinges on whether it holds a higher-low above the ~$68–70 post-ASCO base; losing it puts the recovery trend (~$60 zone, roughly the prior 200-EMA reference) in play.
• Entry math here is the inverse of April: this is buying after a ~2.5x, into MATURING tape, with the next binary distant.

Catalyst Calendar (next 30 days)

• ~2026-06-19 (est.): Cushing's NDA resubmission filing management guided "within the next few weeks" of the 2026-05-27 announcement. The actual filing is the near-term tape mover.
• ~2026-07 (est., just outside window): FDA refuse-to-file vs acceptance decision, typically ~30–60 days post-submission the real near-term binary on whether the late-2026 PDUFA clock even starts.
• Late 2026 (est.): Cushing's PDUFA action date (~6 months post-filing) the major binary; not in this window.
• Q1 already reported 2026-04-30; Q2 print ~early August. No 3-day pre-earnings blackout currently active.

What Would Change Our Mind

• Weekly close below ~$60 recovery trend / ~200-EMA reference breaks, signals the Cushing's optimism is unwinding.
• FDA refuse-to-file or a second CRL on the Cushing's resubmission kills the primary re-rating lever outright.
• FY2026 guide cut below the $950M low end on the Q2 call would confirm the Q1 deceleration is structural, not seasonal.
• Resubmission slips past Q3 2026 pushes the binary out and lengthens the dead-money window.
• Clearing and holding above $91 on the actual resubmission acceptance would re-arm the long for a run at the $135 high target.

Correlation Notes

• Idiosyncratic single-name biotech price is driven by FDA/clinical events (resubmission, PDUFA, ROSELLA readouts), not theme beta. Low correlation to XBI and SPY day-to-day.
• No clean comp cluster: cortisol-modulation / selective glucocorticoid-receptor-antagonist peers are minimal, so there is no peer-breakout confirmation to lean on the the momentum read "cluster" logic does not apply here.
• Binary-catalyst archetype: position risk is event-gap risk, not drawdown-beta. Size to the binary, not to the trend.